TAFRO syndrome, variant of Castleman’s disease: case report
Main Article Content
Keywords
Splenomegaly, Hepatomegaly, Castleman Disease
Abstract
Introduction: Multicentric Castleman’s disease is a rare benign lymphoproliferative disorder that involves multiple enlarged lymph nodes in different areas of the body. Recently, a unique clinic pathological variant of this disease called TAFRO syndrome has been described.
Case report: A 23-year-old male with a history of one year and six months of evolution characterized by generalized lymphadenopathy with, night diaphoresis, dyspnea and weight loss. At the third month, hypertension was diagnosed and 8 months later type 2 diabetes mellitus. After his admission, microcytic anemia, thrombocytopenia, renal dysfunction, pleural effusion and ascites were documented. Based on the findings of the physical examination, a computed tomography scan was performed, where multiple lymph nodes and hepatosplenomegaly were identified. A lymph node biopsy was performed, which reported Castleman’s disease, considering then a diagnosis of TAFRO syndrome due to its association with thrombocytopenia, microcytic anemia, anasarca, fever, renal dysfunction, adenomegaly and hepatosplenomegaly.
Conclusions: There are still doubts about whether it corresponds to a different disease or a subtype of the Castleman disease. It is more frequent in women, occurs in the middle-aged and elderly and given its heterogeneous presentation, it usually represents a diagnostic challenge. Although its management is not standardized, therapeutic options include immunosuppressant such as steroids, cyclosporine, rituximab and anti-IL6.
References
1. Sobrevilla-Calvo J, Avilés-Salas A, Cortés-Padilla D, Rivas-Vera S. Características clinicopatológicas de la enfermedad de Castleman. Experiencia en el Instituto Nacional de Cancerología. Cir Cir. 2009;77:187-92.
2. Guzmán-Fernández M, Campoy-García F, Pereiro-Sánchez M, Sastre-Moral JL. Espectro clínico de la enfermedad de Castleman. Galicia Clin. 2014;75(4):191-4.
3. Srkalovic G, Marijanovic I, Srkalovic M, Fajgenbaum D. TAFRO syndrome:new subtype of idiopathic multicentric castleman disease. Bosn J Basic Med Sci. 2017;17(2):81-4.
4. Simpson D. Epidemiology of Castleman disease. Hematol Oncol Clin North Am. 2018;32(1):1-10.
5. Takai K, Nikkuni K, Shibuya H, Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. [Article in Japanese] Rinsho Ketsueki. 2010;51(5):320–5.
6. Allegra A, Rotondo F, Russo S, CalabròL, Maisano V, Bacci F, et al. Castleman- Kojima disease (TAFRO syndrome) in a Caucasian patient:a rare case report and review of the literature. Blood Cel Mol Dis. 2015;55(3):206-7.
7. Ortiz A, Cárdenas P, Peralta M, Rodríguez H, Frederick G, Ortiz J. Neuro-ophthalmological findings in TAFRO syndrome in a patient from South America, a variant of multicentric Castleman's disease. Int Ophthalmol. 2018;38(4):1641-6.
8. Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103(6):686-92.
9. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol. 2004;43(8):698-704.
10. El-Osta HE, Kurzrock R. Castleman's disease:from basic mechanisms to molecular therapeutics. Oncologist. 2011;16(4):497-511.
11. Gracia-Ramos AE, Cruz-Domínguez MP, Vera-Lastra OL. Enfermedad de Castleman multicéntrica hialina vascular. Una variante de POEMS. Rev Med Inst Mex Seguro Soc. 2013;51(4):464-7.
12. Kubokawa I, Yachie A, Hayakawa A, Hirase S, Yamamoto N, Mori T, et al. The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease. BMC Pediatrics. 2014;14:139.
13. Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91(2):220-6.
14. Alhoulaiby S, Ahmad B, Alrstom A, Kudsi M. Castleman's disease with TAFRO syndrome:a case report from Syria. Oxford Med Case Rep. 2017;6:82-8.
15. Sakashita K, Murata K, Takamori M. TAFRO syndrome:current perspectives. J Blood Med. 2018;9:15-23.
16. Igawa T, Sato Y. TAFRO syndrome. Hematol Oncol Clin North Am. 2018;32(1):107-18.
17. Talat N, Belgaumkar AP, Schulte KM. Surgery in castlemans disease:a systematic review of 404 published cases. Ann Surg. 2012;255:677-84.
18. Koga T, Sumiyoshi R, Kawakami A, Yoshizaki K. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease. Mod Rheumatol. 2019;29:302-5.
19. Matsuhisa T, Takahashi N, Nakaguro M, Sato M, Inoue E, Teshigawara S, et al. Fatal case of TAFRO syndrome associated with over-immunosuppression:a case report and review of the literature. Nagoya J Med Sci. 2019;81:519-28.
20. Ohya E, Mizutani M, Sakaguchi H, Sekine T. Diffuse large B-cell lymphoma during corticosteroid therapy for TAFRO syndrome. Intern Med. 2016;55(19):2861-7.
21. Sakai K, Maeda T, Kuriyama A, Shimada N, Notohara K, Ueda Y. TAFRO syndrome successfully treated with tocilizumab:a case report and systematic review. Mod Rheumatol. 2018;28(3):564-9.
22. JoséFF, Kerbauy LN, Perini GF, Blumenschein DI, Pasqualin D da C, Malheiros DMAC, et al. A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids. Medicine. 2017;96(13):e6271.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.